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Biological synergy developed during administration of combi-
nations of biologically active compounds (BACs) is the key property
extensively used by a number of modern protocols of cancer
chemotherapy. Thus, the ability to manage and predict the
response of biosystem to action of BACs’ combinations is of para-
mount importance for stimulating further progress in this field of
medicine.
One of the most well studied BACs, which exert biological syn-
ergy on simultaneous administration, are aromatic DNA targeting
drugs (Schwab et al., 2000; Evstigneev, 2010, 2013; Woziwodzka
et al., 2013a). The typical examples are the combinations of aro-
matic antibiotics DoxorubicineActinomycin D (Ridge et al., 1994),
DoxorubicineAmsacrine (Bernier et al., 1989),
CamptothecineChloroquine (Sorensen et al., 1997) etc. It is
considered that for the range of aromatic drugs the possible
mechanism of synergy could be associated with two molecular
processes occurring in biological fluid (inside and/or outside cell),
viz. competition for DNA binding sites and non-covalent complex-
ation of drugs with each other (also referred to as hetero-
association or hetero-complexation). If the molecular complexa-
tion lies behind the experimentally observed biological synergy of
aromatic drugs, it follows that some quantitative correlation of
biological parameters and physico-chemical parameters of inter-
molecular interaction should be the case. Implicitly or explicitly, the
search of such correlation has been carried out bymany researchers
during the past 50 years, which has enabled to establish some
important patterns of the biological synergy of aromatic drugs and
formulate the basics of the so-called theory of interceptor-protector
action (the IPA theory). In total, the biological and physico-chemical
data concerning the interaction of DNA binding drugs, accumulated
to date, as well as the level of understanding the mechanism of
biological synergy, are considered to be sufficient for building the
general IPA theory.2. The biological background to the development of the IPA
theory
The biological data accumulated to date with respect to the
systems containing the mixtures of aromatic drug molecules hasbeen extensively reviewed with the most recent contribution given
in refs (Woziwodzka et al., 2013a; Evstigneev, 2013) (see also ref-
erences therein). Here we shall provide some general conclusions
that can be drawn regarding the biological specificity of the com-
binations of aromatic BACs:2.1. The specificity of accumulated biological dataset
The biological data generated to date was mainly obtained on
in vitro level (various human cell lines (e.g. refs (Traganos et al.,
1993; Hill et al., 2011; Skamrova et al., 2014; Panchuk et al., 2015;
Prylutska et al., 2017a; Prylutska et al., 2017b)), bacteria mutagenic
tests (e.g. refs (Woziwodzka et al., 2011; Woziwodzka et al.,
2013b))) with very few instances when the apparent biological
synergy was observed in vivo (e.g. refs (Sadzuka et al., 1995;
Kakuyamanee Iwazaki and Sadzuka, 2001; Prylutska et al., 2014;
Prylutska et al., 2015)). The drugs which are used in experiment
together, most often are categorized for two types: the main drug
which exerts biological effect (say, antibiotic), and the second drug,
which does not have any apparent biological interaction with the
main drug, and is called ‘interceptor’ molecule (in practice, the
conditions of experiment are chosen in a way to minimize the
biological effect of the interceptor drug). The typical biological
experiment is carried out as the measurement of change of bio-
logical effect of the main drug on addition of interceptor molecule,
relative to the action of the drug alone. The corresponding results
are given in qualitative or quantitative form (e.g. the measurement
of IC50 factor as the biological parameter). The main properties of
the measured biological parameter are (Evstigneev, 2013; Traganos
et al., 1991a, 1991b, 1993; Hill et al., 2011; Skamrova et al., 2014;
Panchuk et al., 2015; Kapuscinski et al., 2002; Ganapathi et al.,
1986; Lyles and Cameron, 2002; Bedner et al., 2001; Borowik
et al., 2018):
d the most significant and reproducible changes are observed
in cases when drug-interceptor combinations were admin-
istered and/or present in the vicinity of target cells together.
Sequential administration commonly leads to attenuation or
disappearance of biological synergy;
d strong dependence on concentration of interceptor (dose-
activity relationship);
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d existence of quantitative correlation between the measured
biological parameter and the parameters of molecular
complexation (the equilibrium constant of drug-interceptor
hetero-association). To the best of our knowledge this
property was first noted in ref (Dashwood and Guo, 1993).
with respect to drug-chlorophyllin systems and further
confirmed for other interceptors (Skamrova et al., 2014;
Evstigneev et al., 2005, 2006a, 2006b, 2008, 2011a;
Hernandez Santiago et al., 2009; Buchelnikov et al., 2012;
Buchelnikov and Evstigneev, 2014).2.2. The drugs exert their biological effect mainly due to
complexation with nuclear DNA
Many of known BACs which exert biological synergy in combi-
nation, belong to the group of aromatic DNA intercalators which
directly or indirectly induce biological effect due to covalent or
non-covalent binding with DNA. The most typical examples of such
drugs are antitumor antibiotics (doxorubicin, topotecan, mitoxan-
trone) and mutagens (acridine orange, ethidium bromide,
imidazole-quinoline amines).2.3. The interceptor and protector mechanisms of biological synergy
It was established that the mechanisms of mutual influence of
aromatic heterocyclic compounds on the medico-biological activity
of each other may feature either covalent, or non-covalent type of
action, exerted in specific and non-specific forms. However, the
fundamental similarity of the mechanisms was noted, originating
from the physical interaction of aromatic molecules in mixed so-
lution either at the nucleic acid level or at the level of direct
interaction between the solute molecules. These mechanisms were
formulated in the form of two molecular processes (Fig. 1):Fig. 1. Schematic representation of the ind protector (Skamrova et al., 2014; Traganos et al., 1991a,
1991b; Evstigneev et al., 2005, 2006a, 2006b, 2008, 2011a;
Hernandez Santiago et al., 2009; Buchelnikov et al., 2012;
Buchelnikov and Evstigneev, 2014; Davies et al., 2001; Chin
et al., 2012; Maria Johnson et al., 2003a), i.e. competition of
the drug and interceptor for DNA binding sites leading to
removal of the drug from DNA as a result of interceptor-DNA
binding, and
d interceptor (Traganos et al., 1991a, 1991b, 1993; Hill et al.,
2011; Skamrova et al., 2014; Panchuk et al., 2015;
Woziwodzka et al., 2011, 2013b; Kapuscinski et al., 2002;
Ganapathi et al., 1986; Lyles and Cameron, 2002; Bedner
et al., 2001; Borowik et al., 2018; Dashwood and Guo, 1992,
1993; Evstigneev et al., 2005, 2006a, 2006b, 2008, 2011a;
Hernandez Santiago et al., 2009; Buchelnikov et al., 2012;
Buchelnikov and Evstigneev, 2014; Davies et al., 2001; Chin
et al., 2012; Maria Johnson et al., 2003a; Piosik et al., 2002,
2003, 2005, 2010; Ulanowska et al., 2005, 2007; Tachino
et al., 1994; Pietrzak et al., 2006, 2008; Gołunski et al.,
2013, 2015; Banerjee et al., 2011; Kharasch and Novak,
1981; Raiczyk and Pinto, 1988; Ramu et al., 2000; Arimoto
et al., 1993; Ardelt et al., 2001; Ridge et al., 1994), i.e.
hetero-association between the Drug and Interceptor leading
to formation of inactive hetero-complexes unable to bind
with DNA (an analogue of host-guest interaction).
The interceptor mechanism has long been known and the
molecules acting by this mechanism were termed as ‘interceptor
molecules’ or ‘scavengers’ (Woziwodzka et al., 2013a; Evstigneev,
2013; Dashwood and Guo, 1992; Gołunski et al., 2016; Odin,
1997). However, the existence of two molecular mechanisms,
operating simultaneously in drug-interceptor-DNA systems, sug-
gests that the term ‘interceptor molecule’ should therefore be un-
derstood more broadly.
The most typical aromatic interceptor molecules, for which the
interceptor-protector hypothesis is commonly discussed as beingterceptor and protector mechanisms.
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d methylxanthines (caffeine, theophylline, pentoxifylline)
(Woziwodzka et al., 2011, 2013a, 2013b; Evstigneev, 2013;
Traganos et al., 1991a, 1991b, 1993; Hill et al., 2011; Skamrova
et al., 2014; Sadzuka et al., 1995; Kakuyamanee Iwazaki and
Sadzuka, 2001; Kapuscinski et al., 2002; Ganapathi et al.,
1986; Lyles and Cameron, 2002; Bedner et al., 2001;
Evstigneev et al., 2006a, 2006b, 2008, 2011a; Hernandez
Santiago et al., 2009; Buchelnikov et al., 2012; Buchelnikov
and Evstigneev, 2014; Davies et al., 2001; Chin et al., 2012;
Maria Johnson et al., 2003a; Piosik et al., 2002, 2003, 2005,
2010; Ulanowska et al., 2005, 2007; Gołunski et al., 2013,
2015, 2016; Banerjee et al., 2011);
d polyphenols (vitamin B2) (Woziwodzka et al., 2013a;
Evstigneev, 2013; Evstigneev et al., 2005, 2008; Kharasch and
Novak, 1981; Raiczyk and Pinto, 1988; Ramu et al., 2000;
Odin, 1997);
d porphyrins (of which chlorophyllin is most well studied)
(Woziwodzka et al., 2013a; Evstigneev, 2013; Dashwood and
Guo, 1992, 1993; Buchelnikov and Evstigneev, 2014; Tachino
et al., 1994; Pietrzak et al., 2006, 2008; Arimoto et al., 1993;
Ardelt et al., 2001);
d fullerene C60 (the most recent discovered interceptor mole-
cule) (Skamrova et al., 2014; Panchuk et al., 2015; Prylutska
et al., 2014, 2015, 2017a, 2017b; Borowik et al., 2018;
Bilobrov et al., 2019).2.4. The physico-chemical nature of drug-interceptor interaction
It was noted that aromatic BACs contain conjugated aromaticFig. 2. Structures of the typical interceptor molecules.heterocycles which make them essentially rigid and flat objects.
Such molecules feature strong p-stacking interactions with each
other which is considered to be the principal driving force stabi-
lizing intercalated complexes of aromatic drugs with DNA
(Evstigneev, 2010; Kostjukov et al., 2009; Evstigneev and
Shestopalova, 2014), as well as drug-interceptor hetero-com-
plexes (Borowik et al., 2018; Larsen et al., 1996; Kostjukov et al.,
2011; Evstigneev, 2014). This property allows one to predict the
biological interaction for other drugs’ combinations. In fact, the
prediction of interceptor action of pentoxifylline (Woziwodzka
et al., 2011, 2013b) and fullerene (Skamrova et al., 2014; Panchuk
et al., 2015) has been made based on the knowledge of the
physico-chemical nature of stabilizing property of p-stacking.
The above-mentioned specificities of drug-interceptor-DNA
systems were considered as starting point for creating the IPA
theory.
3. The early stage of development of the IPA theory
3.1. General principles of the quantitative IPA theory
3.1.1. The goal
As discussed above, the biological data accumulated to datewith
respect to biological synergy observed on simultaneous adminis-
tration of a combination of aromatic BACs (i.e. drug-interceptor
pairs) contain a correlation of the measured biological parameter
with physico-chemical parameters of molecular complexation.
Hence, the aim of the IPA theory should be the prediction of relative
change in biological effect induced by addition of interceptor
molecule to biological system containing aromatic drug.
3.1.2. The system to investigate
The fundamental mechanisms of biological synergy, viz. pro-
tector and interceptor, in general case may operate simultaneously
and act on the level of drug-interceptor interaction (the interceptor
mechanism) or drug-DNA/interceptor-DNA interaction (the pro-
tector mechanism). It follows that the minimal model of synergistic
interaction should be the three-component drug-interceptor-DNA
system.
3.1.3. The method
In the majority of papers related to the IPA theory (i.e. those
which discuss the three- or more-component systems of different
interacting molecules including biopolymer), the search of the link
between biological and physico-chemical parameters used solely
equilibrium thermodynamics approach. It follows that the quanti-
tative IPA theory should use at least two fundamental laws of
equilibrium thermodynamics, viz. themass balance law and the law
of mass action, written with respect to drug-interceptor-DNA
system.
3.1.4. The link to biological experiment
As long as the interceptor/protector mechanisms are fully
physico-chemical processes, their effect should be expressed in
terms of physico-chemical parameters of molecular complexation,
i.e. equilibrium complexation constants and equilibrium concen-
trations. The utilization of relative change of biological parameter
as a measure of biological effect induced by addition of interceptor
(see section 2) suggests that the key quantities which could be
obtained from the solution of equations of mass balance law, are
mole fractions of different types of drug-DNA complexes. The latter
could then be associated with the measured biological parameter.
The principles outlined above explain the evolution of the IPA
theory from the early stage dated back to 2000 up to now, which
will be detailed below.
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The reduced IPA theories are characterized by consideration of
single molecular process, interceptor or protector, or any other
reduction of the dynamic equilibrium in solution, and the use of
polymeric DNA as a model of bioreceptor.
The neglecting of the interceptor mechanism results in classical
competitive binding scheme well known in enzyme (e.g. ref (Wang
et al., 1998; Peacock and Jaynes, 2017)) as well as nucleic acid
chemistry (e.g. refs (Zasedatelev et al., 1971; McGhee and von
Hippel, 1974; Nechipurenko et al., 1984; Baranovskii et al., 2011)),
which uses classical Scatchard or McGhee d von Hippel ap-
proaches for describing molecular equilibrium in three-component
systems. The mole fractions (q) of X-DNA and Y-DNA complexes
(3.1a) and the mass balance law (3.1b) in X-Y-DNA system are
written as8>><
>>:
qX ¼ KXNx1ð1 nXqX  nYqY Þ

1 nXqX  nYqY
1 ðnX  1ÞqX  ðnY  1ÞqY
nX1
qY ¼ KYNy1ð1 nXqX  nYqYÞ

1 nXqX  nYqY
1 ðnX  1ÞqX  ðnY  1ÞqY
nY1 ; (3.1a)
x0 ¼ x1 þ qXN0
y0 ¼ y1 þ qYN0 ; (3.1b)
where x1, y1 and x0, y0 are the concentrations of monomers and
total concentrations of drugs X and Y, respectively; N0 is total DNA
concentration in base pairs per mole; nX , nY and KXN , KYN are the
number of base pairs per one bound ligand (the binding site size)
and equilibriumDNA complexation constant, respectively. The pure
competitive binding scheme (3.1) should be considered here as a
potentially important partial case of the IPA theory.
Another partial case presented in most general case in ref
(Gołunski et al., 2015). was related to the most widely spread case
when the protector mechanism could be ignored and the hetero-
association between drug and interceptor completely governs the
biological synergy. This case was successfully applied to drug-
chlorophyllin-DNA (Pietrzak et al., 2006, 2008) and drug-
methylxanthine-DNA (Piosik et al., 2010; Gołunski et al., 2015,
2016) systems. The basic equations to treat dynamic equilibrium
were obtained by merging the hetero-association model
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where C, K, r, n are concentrations, equilibrium binding constants,
binding density (equivalent to q in eq. (3.1)) and site size, respec-
tively; KI is the drug-DNA binding constant; the subscripts ‘A’ and
‘C’ stand for the drug (A) and interceptor (C); the subscript ‘T’ stands
for the total concentration. The quantities CAC , CAA, CCC describe the
concentration of ‘neighborhoods’ of certainmolecules in all types of
complexes in solution; CA and CC are the monomer concentrations.
eqs. (3.2b), (3.2c) represent the mass balance law for the drug and
interceptor. Apart from neglecting the protector mechanism, eq.
(3.2) consider partial case of low drug concentration when its self-
association may be limited by dimerization.
The first account for both protector and interceptor mechanisms
was accomplished in ref (Baranovsky et al., 2009) and later on in ref
(Gołunski et al., 2013). by merging eq. (3.1) with simple 1:1 hetero-
association of drug and interceptor molecules. In this case eq. (3.1b)
should be replaced with
x0 ¼ x1 þ qXN0 þ Khx1y1
y0 ¼ y1 þ qYN0 þ Khx1y1 ; (3.3)
where Kh is the hetero-association constant.
This scheme was successfully used to describe spectrophoto-
metric data in drug-methylxanthine-DNA systems (Gołunski et al.,
2013, 2016; Baranovsky et al., 2009).3.3. ‘Oligomer’ IPA theories
The ‘oligomer’ IPA theories are characterized by account for the
protector and interceptor mechanism from one side, and attempts
to remove limitation to 1:1 hetero-association and dimeric drug
self-association, from the other.
In order to describe drug/interceptor-DNA binding the simplest
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the binding site size was taken equal to n ¼ 4 (this value in first
approximation well matches the typical n for DNA intercalators),
merged with the indefinite hetero-association model (Davies et al.,
2000). The first application of this approach dates back to 2000
(Veselkov et al., 2000) and was used until 2002 (Davies et al., 2001,
2002; Veselkov et al., 2002) when it was replaced by more general
scheme to be described below.
The principal disadvantage of all models outlined above is the
absence of any link to biological experiment. The papers cited just
used the solution of mass balance equations to demonstrate the
importance of interceptor/protector mechanisms or to correlate the
monomer drug concentration with the observed biological effect
(e.g. ref (Gołunski et al., 2013)). The first quantitative link to bio-
logical data measured in drug-interceptor-DNA systems was sug-
gested in 2005 (Evstigneev et al., 2005) and successfully used until
now in many followed up works (Evstigneev, 2010; Skamrova et al.,
2014; Evstigneev et al., 2005, 2006a, 2006b, 2008, 2011a;
Hernandez Santiago et al., 2009; Buchelnikov et al., 2012, 2013a;
Buchelnikov and Evstigneev, 2014). The essence of this approach is
to evaluate the effect of addition of interceptor (Y) to the system
containing the drug (X) and DNA (N) by means of two factors, RD
and AD, calculated under conditions of ‘switched off’ interceptor
and/or protector mechanisms:
RD ¼
f XCð0Þ  f XCðcÞ
f XCð0Þ  f XCðhÞ
; AD ¼
f XCð0Þ  f XC
f XCð0Þ
; (3.4)
where f XCð0Þ is the mole fraction of X-DNA complexes with ‘switched
off’ hetero-association and Y-DNA complexation (Kh ¼ 0, KYN ¼ 0);
f XCðcÞ is the mole fraction of X-DNA complexes under condition of
‘switched off’ X-Y hetero-association and ‘switched on’ complexa-
tion of Y with DNA (Kh ¼ 0, KYNs0); f XCðhÞ is the mole fraction of X-
DNA complexes under condition of ‘switched on’ X-Y hetero-
association and ‘switched off’ complexation of Y with DNA
(Khs0, KYN ¼ 0); f XC is the relative amount of drug X bound to DNA
in the presence of Y, when both mechanisms are operating.
The range of RD >1 corresponds to the predominance of Y-DNA
complexation over X-Y hetero-association (i.e. the ‘protector action’
of ligand Y) and RD <1 corresponds to hetero-association being the
major contribution to the displacement of drug molecules from
DNA (i.e. the ‘interceptor action’ of ligand Y). As long as the drug X
exerts its biological action mainly via complexation with DNA, and
so, the quantity AD may be used as a measure of relative change of
biological effect of the drug X in the three-component system, X-Y-
DNA, on addition of interceptor molecule Y (themost typical case of
experimentallymeasured relative biological effect directly linked to
the AD factor is the standard IC50 or LC50 parameters, or other cell
quantities, measured in vitro; see sections 4.2 and 6).
The computation of the mole fractions in eq. (3.4) is accom-
plished within the framework of the ‘oligomer’ model, constructed
by merging the indefinite hetero-association (Davies et al., 2000)




























N0 ¼ N1ð1þ KXNx1 þ KYNy1Þwhere N1 is the concentration of tetrameric DNA binding sites; KX ,
KY are the self-association constants. Solution of eq. (3.5) with
respect to x1, y1, N1 allows one to compute eachmole fraction given
in eq. (3.4) as f XC ¼ KXNx1N1x0 .
The ‘oligomer’ model based on eqs. (3.4), (3.5) was successfully
applied to a wide range of drug-interceptor-DNA systems and
enabled to provide the first estimate of experimentally measured
and theoretically calculated relative change of biological effect (the
AD factor), as well as to evaluate the relative contribution of the
interceptor and protectormechanisms (the RD factor). However, the
disadvantage of the described approach was a certain lack of
generality:
(i) Utilization of the most simple Scatchard model of drug/
interceptor-DNA complexation. The use of McGhee d von Hippel
model would be preferable;
(ii) Utilization of approximate indefinite hetero-association
model (Davies et al., 2000) accounting for limited types of
hetero-complexes (see ref (Evstigneev et al., 2011b) for more
discussion);
(iii) utilization of the simplest case of 2-component drug-
interceptor equilibrium in the presence of DNA. Consideration of
general N-component mixture of various drugs with various
interceptor molecules would be preferable.
4. The general IPA theory
The elements of the theory, removing the drawbacks of the early
IPA theories described above, were published in series of works
(Skamrova et al., 2014; Evstigneev et al., 2008, 2011a; Buchelnikov
et al., 2012, 2013a; Buchelnikov and Evstigneev, 2014). Below these
results will be compiled into the general IPA theory.4.1. Formulation of the main statements of the theory
Let us consider the ðN þ 1Þ -component system containing
polymeric DNA, the main drug X exerting biological effect which is
measured in in vitro experiment, and ðN  1Þ different interceptor
molecules, able to non-covalently complex with DNA andwith each
other. The interceptor molecules will be designated as Y1, Y2,…, YN-
1 and the DNA as P. Let us formulate five principal assumptions of
the IPA theory:
(i) Biological effect which is measured in in vitro experiment is
mainly determined by complexation with nuclear DNA, and the
interceptor molecules Y1, Y2, …, YN-1 do not biologically interfere
with the effect of drug X. At least for the range of intercalating drugs
and interceptors discussed in section 2 this assumption is valid;
(ii) Biological effect of drug X, under first approximation, may be
considered proportional to the mole fraction of X-DNA complexes,
f XC . Indirectly, this assumption is confirmed by proportionality of
the observed in vitro biological effect with the concentration, x1, of
free drug X not bound with interceptors or DNA (e.g. ref
(Woziwodzka et al., 2013b));
(iii) biological synergy of drugs’ combination X-Y1-Y2-… -YN-1 isy1N1
; (3.5)
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by any other routewhen the drugs X, Y1, Y2,…, YN-1 appear together
in the vicinity of DNA. As discussed in section 2 this assumption is
supported by the fact that the most pronounced change in bio-
logical effect is achieved on simultaneous administration of drug-
interceptor combinations;
(iv) The processes of hetero-association X-Y1, X-Y2, …, X-YN-1
and X-DNA, Y1-DNA, Y2-DNA, …, YN-1-DNA complexation are non-
covalent and the system may be considered at local thermody-
namic equilibrium. This assumption is partly supported by
reversibility of the observed experimental changes in vitro (see
section 2).
(v) equilibrium constants of hetero-association and DNA
complexation, measured in separate physico-chemical ex-
periments under solution conditions close to physiological,
may be considered transferrable to the in vitro conditions.
The validity of the set of these assumptions is proved by the
ability of the IPA theory to quantitatively predict the relative change
in biological effect for given drug-interceptor combinations. There
are two immediate consequences from the set of formulated
statements:
(i) Any experimentally observed biological synergy of the drug X
and the interceptors Y in vitro is solely due to the effects of mo-
lecular complexation: X/Y-DNA complexation and X-Y hetero-
association. Hence, at least two molecular processes govern the
biological synergy (Fig. 1), viz. the interceptor (hetero-association
between the drug and interceptors leading to formation of inactive
hetero-complexes unable to bind with DNA) and protector
(competition of the drug and interceptors for DNA binding sites
leading to removal of the drug from DNA as a result of interceptor-
DNA binding);
(ii) Correlation of the observed in vitro biological effect with the
physico-chemical parameters of molecular complexation (i.e.
equilibrium complexation constants) should be the case. As dis-
cussed in section 2 this statement is supported by experimental
observations.4.2. Link to biological experiment
The general IPA theory uses the factors RD and AD developed in
‘oligomer’ theories (see section 3.3) in order to quantify biological
data measured in ðN þ 1Þ -component drug-interceptors-DNA
system. Their formulation in such system is generally similar to
that presented in eq. (3.4), however, it will be given here in terms of
binding densities, qi, of the i-th ligand ði21…NÞ with DNA (the
fraction of DNA bound ith ligand relative to DNA concentration P0).
If the main drug X exerting biological effect has index i ¼ 1, the




















where qð0Þ1 is calculated under condition of ‘switched off’ hetero-
association and Y-DNA complexation (the hetero-association con-
stants and interceptors-DNA binding constants equal to zero); qðcÞ1 is
calculated under condition of ‘switched off’ X-Y hetero-association
and ‘switched on’ complexation of Y with DNA (only the hetero-
association constants equal to zero); qðhÞ1 is calculated under con-
dition of ‘switched on’ X-Y hetero-association and ‘switched off’
complexation of Y with DNA (only the equilibrium constants of
interceptors-DNA binding equal to zero); q1 is the binding density
when all equilibrium constants are non-zero.It is seen from eq. (4.1) that the AD factor is proportional to the
fraction of DNA bound ligand X, hence, as declared in statement (ii)
(see section 4.1), it represents the quantitative measure of biolog-
ical effect in ðN þ 1Þ -component drug-interceptors-DNA system
and is given as a change of biological effect of drug X on addition of
interceptors Y relative to the case when interceptors are absent. In
this sense the AD factor is similar to standard biological quantities,
such as IC50, measured in in vitro experiment and expressed as
dimensionless parameters. The examples of re-calculating the
experimentally measured in vitro biological effect in terms of AD
factor are given in refs. (Evstigneev, 2010; Skamrova et al., 2014;
Evstigneev et al., 2008, 2011a; Buchelnikov and Evstigneev, 2014).
The RD factor has the meaning of a ratio of strength of protector
to interceptor mechanisms. The range of RD >1 corresponds to the
predominance of protector action and RD <1 corresponds to pre-
dominance of the interceptor action.4.3. The main equations of the IPA theory
4.3.1. The system of mass balance equations
The most general description of the ðN þ 1Þ -component system
of interacting molecules and DNA can be given by means of
merging the model of N-component hetero-association
(Buchelnikov et al., 2013b) with McGhee d von Hippel equation
(3.1) extended to the case of N-competing ligands. The model
(Buchelnikov et al., 2013b) is considered to be the most exact
among alternative approaches suggested so far and reviewed
above, free of any limitation to the length of aggregates or types of
hetero-complexes (see ref (Buchelnikov et al., 2019) for review).
For the system of interacting molecules in the presence of
polymeric DNA having the total concentration of nucleotide pairs






























where Cð0Þi and Ci are the total and monomer concentrations of the
i-type molecules; CðhetÞi ¼ vZhetv ln Ci is the concentration of the i-type
molecules existing in all possible homo- and hetero-complexes of
any length in N-component mixture excluding DNA; Zhet is the
grand partition function of the N-component mixture excluding
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I and 1 are N  N and N  1 unit matrices; Kij and Kii are the
equilibrium hetero- and homo-association constants for complex-










is the standard DNA binding densities for ith ligand with
complexation constant KiP and binding site size ni. The binding
density can be directly related to the mole fraction, f ðiÞC ., used in
‘oligomer’ theories as f ðiÞC ¼ qi P0Cð0Þi , which establishes direct link be-
tween the RD, AD factors in eqs. (3.4) and (4.1).
It is worth noting that the grand partition function, Zhet, used in
eq. (4.2) and taken from the general hetero-association model
(Buchelnikov et al., 2013b), reduces to all major hetero-association
models, including those reviewed above and used in early IPA
theories. Another important issue to keep in mind is that the
equations for qi describe the case of non-cooperative and non-
specific drug/interceptor binding with DNA. If the drugs feature
some specificity of binding, the expression for qi in eq. (4.2) can be
replaced with the corresponding expressions known from modifi-
cations of standardMcGheed von Hippel theory (e.g. refs (McGhee
and von Hippel, 1974; McGhee, 1976)) and well elaborated in
nucleic acid and enzyme chemistry.
Solution of eq. (4.2) results in the set of monomer concentra-
tions, Ci, and drug binding densities, qi, which enable to compute
the concentration of any type of complex present in ðN þ 1Þ
-component system. In particular, it is possible to compute quan-
tities for the drug X under various combinations of ‘switched on’
and ‘switched off’ equilibrium binding constants, Kij and KiP ,
described in eq. (4.2). It follows that eq. (4.2) provide complete
quantitation of the drug-interceptors-DNA system in terms of the
IPA theory.4.3.2. Test of the appropriateness of the mass balance equations
The mass balance equation (4.2) use equilibrium homo-/hetero-
association constants, Kij, and DNA complexation constants, KiP as
the main physico-chemical parameters of molecular complexation.
All these parameters were previously derived for all major drug-
interceptor-DNA pairs in similar solution conditions (see refs
(Evstigneev, 2010; Evstigneev et al., 2008; Evstigneev, 2014) and
references therein) in separate one- (self-association) or two-
component (hetero-association and ligand-DNA complexation)
systems. The question is whether these parameters are trans-
ferrable to more complex ðN þ 1Þ -component system (i.e. are there
any specific cooperative effects in multicomponent system which
cannot be observed in more simple two-component systems)? This
question was subjected to experimental investigation in refs.
(Evstigneev et al., 2005, 2006a, 2006c, 2006d, 2007; Buchelnikovet al., 2012, 2013c). Using NMR spectroscopy and spectrophotom-
etry for various drug-interceptor pairs it was shown that the
equilibrium constants derived from two-component systems are
transferrable to multicomponent solution.4.3.3. Parameterization of the mass balance equations
In order to make the mass balance equation (4.2) applicable for
analysis of the competitive binding under in vitro conditions in
biological systems, it is necessary to select appropriate concentra-
tions of the components, Cð0Þi , P0, applying the common assumption
(v) in such analyses (see section 4.1) that the equilibrium binding
constants appearing in eq. (4.2) and measured in independent
physico-chemical experiments are the same when dealing with
biological systems. The set of such concentrations was previously
termed as quasi-physiological and determined separately for the
‘oligomer’ (4.3a) (Evstigneev, 2010; Evstigneev et al., 2008, 2011a)
and ‘polymer’ (4.3b) (Buchelnikov et al., 2012) models of DNA used
in IPA theories:
Cð0Þ1 ¼ 10 mM; C
ð0Þ
i  var; P
oligomer
0 ¼ 10 mM; (4.3a)
Cð0Þ1 ¼ 10 mM; C
ð0Þ
i  var; P0 ¼ 40 mM; (4.3b)
where ‘var’ for the concentrations of interceptor molecules, Cð0Þi ,
means the typical concentration range used to study the synergy of
drug-interceptor interaction (e.g. from 0 to units of mM for meth-
ylxanthines (Traganos et al., 1991a; Traganos et al., 1991b; Lyles and
Cameron, 2002; Bedner et al., 2001)).
The concentrations (4.3) were previously deduced from in vitro
data on the reduction in toxicity of the antitumor antibiotics
doxorubicin and novatrone in human leukemia cell lines on addi-
tion of caffeine using the ‘oligomer’ model ðn ¼ 4Þ (Evstigneev,
2010; Evstigneev et al., 2008). Recently this result was confirmed
in quantification of apoptosis-concentration curve for the anti-
cancer agent topotecan (Evstigneev et al., 2011a) and drug-
induced granulation of hetero-chromatin in human buccal
epithelium cells (Skamrova et al., 2014). In ref (Buchelnikov et al.,
2012) it was shown that the ‘oligomer’ model is a particular case
of the general ‘polymer’ model, and for simple aromatic drugs no
significant error in quantitation of the drug-interceptor-DNA sys-
tem is expected when switching between the ‘polymer’ and the
‘oligomer’ models. It follows that applying the scaling factor of n ¼
4 to the DNA concentration, Poligomer0 ¼ P0=4, the set of quasi-
physiological conditions for polymeric DNA may be summarized
as (4.3b), where P0 is expressed in units of base-pairs (or phos-
phates) and Poligomer0 is expressed in tetrameric binding sites.
Another important issue necessary to take into consideration is
the magnitudes of drug/interceptoreDNA binding constants, which
may depend on physico-chemical method (e.g. NMR or spectro-
photometry), DNA model (e.g. oligomer or polymer) and binding
model (e.g. Scatchard or McGhee d von Hippel) used for their
determination. In ref (Buchelnikov et al., 2012) this question was
subjected to detailed numerical analysis. The re-derivation of the
quasi-physiological conditions (4.3) using the AD factor referenced
against the in vitro data in drug-caffeine-DNA systems confirmed
the appropriateness of conditions (4.3) with respect to dispersion
in magnitudes of microscopic binding constants and binding site
sizes in eq. (4.2). However, it was recommended to always use the
values of binding parameters determined in similar solution con-
ditions (see refs (Evstigneev et al., 2008; Evstigneev, 2014) for re-
view) using the same DNA model and binding scheme as those
employed in eq. (4.2).
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theory
The parameterization of mass balance equation (4.2) raises a
question to what extent an accuracy of estimation of the quasi-
physiological conditions (4.3) can influence the predicted magni-
tude of the AD factor? This question is linked to amore fundamental
problem (v) (see section 4.1) of how well the magnitudes of
complexation constants and concentrations measured in separate
physico-chemical experiments agree with their magnitudes in real
cell.
In ref (Evstigneev et al., 2011b) the sensitivity of the AD factor to
variation of quasi-physiological conditions was investigated in
detail. Assuming the typical error of experimental determination of
the binding parameters (binding constants, binding site sizes and
concentrations) enabled to conclude that there are three sets of
parameters in eq. (4.2) which have the greatest impact on the AD
factor, viz. the hetero-association constants, Kij, and the ligand-DNA
binding constants, KiP . The parameters of self-association, Kii, and
the concentrations, Cð0Þi , P0 exert minor influence. This result is
quite expected because Kij are directly linked with the strength of
the interceptor mechanism, and KiP are linked with the protector
mechanism and the fraction of drug-DNA complexes. Further
analysis showed that within the typical error of biological experi-
ment (i.e. setting the allowed dispersion of the AD factor to 15%) and
depending on the combinations studied, on average ca. 100% range
of deviation of the binding parameters in eq. (4.2) appears to be
acceptable. There is a very important outcome because it reveals
the fundamental ‘inertness’ of the AD factor with respect to varia-
tion of the physico-chemical parameters of interaction. In previous
studies this effect was also noted for particular combinations of the
ligands (Evstigneev, 2010; Evstigneev et al., 2006a, 2006b, 2008,
2011a), and can presumably be considered as a general property of
the drug-interceptor-DNA systems. This is important because the
property of ‘inertness’, in part, justifies the use of binding param-
eters in eq. (4.2) (derived from independent physico-chemical ex-
periments; see ref (Kostjukov et al., 2011) for review) for estimation
of relative biological effect in the IPA theory, as well as to use rough
estimate of the concentrations in quasi-physiological conditions
(4.3). It also provides indirect explanation to the reported successes
in theoretical description of the dependence of the in vitro bio-
logical effect for various DNA binding drugs and interceptor mol-
ecules, i.e. refs. (Evstigneev, 2010; Skamrova et al., 2014; Evstigneev
et al., 2006a, 2008, 2011a; Buchelnikov and Evstigneev, 2014).
However, the general correspondence of the magnitudes of binding
parameters to pH, ionic strength and temperature of the biologicalFig. 3. Examples of the RD , AD factors calculated for drug-caffeine-DNA system as a func
doxorubicin, NOR d norfloxacin, NOV d mitoxantrone, PF d proflavine, PI d propidium isystem under study is the important factor, making the parame-
terization of eq. (4.2) truly meaningful.4.4. General patterns of the RD, AD factors
Numerical analysis of the dependence of RD, AD factors on
concentrations Cð0Þi , P0 (in the ‘polymer’ theory) and x0, y0, N0 (in
the ‘oligomer’ theory) was accomplished in refs. (Evstigneev, 2010;
Skamrova et al., 2014; Evstigneev et al., 2005, 2006a, 2006b, 2008,
2011a; Hernandez Santiago et al., 2009; Buchelnikov et al., 2012).
The typical RD, AD curves for caffeine (CAF) as classical interceptor
molecule are given in Fig. 3. It is seen that for certain combinations
the protector action (RD >1) is dominant over the interceptor action
(PI, NOR), and both mechanisms are of comparable efficacy (RDz1)
for the other combinations (PF, DOX, NOV). The very rare case of
predominant contribution from the interceptor action (RD <1) was
noted for NOV-flavinmononucleotide-DNA combination
(Evstigneev, 2010; Evstigneev et al., 2008) due to strong hetero-
association amplified by intermolecular hydrogen bond between
the drug and interceptor (Veselkov et al., 2005). In the range of
relatively small interceptor concentrations the concentration
dependence of the RD factor is negligible, whereas at high con-
centrations it levels off to RDz1. Analysis performed in refs
(Evstigneev, 2010; Evstigneev et al., 2008) based on the ‘oligomer’
IPA theory showed that in the extreme limit of a great excess of
interceptor molecules in solution, i.e. y0/∞, evaluation of the
lim
y0/∞
RD ¼ 1 is unity, which means that there is an equal contri-
bution of the ‘interceptor/protector’mechanisms. Another extreme
limit, lim
y0/0






Eq. (4.4) can be used to estimate the interrelation between the
interceptor and protector actions in any X-Y-DNA.
The AD factor demonstrates saturation profile indicating the
removal of drug molecules from DNA on addition of interceptor.
Themost important outcome from analysis of the right plot in Fig. 3
is the ability to categorize drugs in descending order for their
sensitivity to the addition of interceptor, i.e. PF > NOR > NOV >
DOX > PI. It means that the largest synergistic effect on addition of
CAF at mM concentrations is expected for the mutagen PF and the
lowest change for the mutagen PI with DNA. Analysis (Evstigneev,
2010; Evstigneev et al., 2006a, 2008) also showed that the
sequence of drugs very weakly depends on N0 and x0. Moreover,tion of caffeine concentration (re-drawn from ref (Evstigneev et al., 2008)). DOX d
odide.
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The approximation is good only if the effects of the studied
drugs differ from each other by more than ca. 15%e20% in K2h=KXN
units. Nevertheless, just using values of the equilibrium hetero-
association constant for X-Y and the X-DNA complexation con-
stant, eq. (4.5) can be used to predict within a 20% accuracy the
relative effect of addition of interceptor molecule to one drug
relative and to another (all other conditions be equal; the detailed
procedure for comparing different drugs in AD terms is given in refs
(Evstigneev, 2010; Evstigneev et al., 2008)). In fact, eq. (4.5) also
provides a rationale for the direct regulation of biological activity in
drug-interceptor systems by varying the equilibrium hetero-
association and complexation constants in different systems.
The RD, AD curves demonstrate relatively weak dependence on
the drug and DNA concentrations even at order of magnitude
variation of their values (Evstigneev et al., 2005) (i.e. the very
approximate quasi-physiological conditions do not affect qualita-
tive conclusions drawn from analysis of RD, AD concentration
dependences).5. Reduction of the general IPA theory to major partial cases
5.1. Reduction of the ðN þ 1Þ -component to three-component
drug-interceptor-DNA system
The three-component drug-interceptor-DNA system is currently
the most demanded case of the IPA theory. The reduction of eq.
(4.2) down to the three-component case is accomplished by leaving
here only two equations for the drug ði ¼ 1Þ and interceptor ði ¼ 2Þ.
The next step would be the reduction of the grand partition func-
tion, Zhet, to the 2-component case of hetero-association. The
general approach to perform this operation was given in ref.
(Buchelnikov et al., 2013b). The final equations representing (4.2)-
like mass balance equations were obtained in refs (Buchelnikov
et al., 2012; Evstigneev et al., 2011b). for the case of hetero-
association model without any restrictions; in ref (Evstigneev
et al., 2011a). for the case of 1:n hetero-association with two
types of drugs (antibiotic topotecan in lactone and carboxylate
forms) and one type of interceptor. Eq. (3.2) of the reduced ‘poly-
mer’ theory represent the standard case of 2:n hetero-association
model which also directly follows from Zhet (Buchelnikov et al.,
2013b).5.2. Reduction of the ‘polymer’ to the ‘oligomer’ theory
Once the reduction to the three-component drug-interceptor-
DNA system is carried out, further transformation of the ‘polymer’
to ‘oligomer’ equations of the IPA theory becomes simple (see ref
(Buchelnikov et al., 2012) for more details). Assuming that poly-
meric DNA consists of non-overlapping sites of equal length (four
nucleotide pairs) for the drug and the interceptor, it is necessary to
put nX ¼ 1, nY ¼ 1 in eq. (3.1) which yields the standard linear
Scatchard equations reducing down to third equation in eq. (3.5) of
the ‘oligomer’ theory.
Evaluation of the first two equations in eq. (3.5) representing the
contribution from hetero-association to dynamic equilibrium
within the framework of the ‘oligomer’ theory was accomplished in
ref. (Buchelnikov et al., 2013b).5.3. The case of the ‘oligomer’ theory ignoring aggregation
An accurate determination of the RD and AD factors can be made
by solution of the system of mass balance equations. In case of
considering self- and/or hetero-association beyond the dimer stage,
an accurate analytical solution of that system is unlikely to be
possible. However, if self-association of X and Y molecules can be
excluded from the analysis and only 1:1 hetero-association
considered, then the system of mass balance equations may be
simplified down to eq. (5.1). Such assumptions are reasonable
because at physiological concentrations (mM) the self-association of
aromatic drugs as well as high order hetero-association may not be
significant.8<
:
x0 ¼ x1 þ KXNx1N1 þ Khx1y1
y0 ¼ y1 þ KYNy1N1 þ Khx1y1
N0 ¼ N1 þ KXNx1N1 þ KYNy1N1
: (5.1)
Under the set of conditions

N0 ¼ x0; x0≪ 1Kh; N0≪ 1KYN
	
solu-





1þ cp þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ cpffiffiffiffiffiffiffiffiffiffiffi
1þ bp þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ bp ,
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 4ap ffiffiffiffiffiffiffiffiffiffiffi1þ bp  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ bpffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 4ap ffiffiffiffiffiffiffiffiffiffiffi1þ cp  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ cp
ADðRD≪1Þ ¼
2ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 4ap  1,
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 4ap ffiffiffiffiffiffiffiffiffiffiffi1þ cp  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ cpffiffiffiffiffiffiffiffiffiffiffi
1þ cp þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ cp
ADðRD[1Þ ¼
2ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 4ap  1,
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ 4ap ffiffiffiffiffiffiffiffiffiffiffi1þ bp  ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ bpffiffiffiffiffiffiffiffiffiffiffi
1þ bp þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi1þ 4aþ bp
;
(5.2)
where a ¼ KXNx0, b ¼ KYNy0, c ¼ Khy0.
It was shown (Evstigneev et al., 2008) that the solution (5.2) is
applicable to certain drug-interceptor pairs.5.4. The case of the ‘oligomer’ theory ignoring interceptor binding
with DNA
One of the most widely spread partial case of the drug-
interceptor-DNA systems is condition of negligible interceptor
binding with DNA, which allows to exclude the protector mecha-
nism from analysis. This case was extensively utilized in analysis of
the synergy in drug-chlorophyllin (Dashwood and Guo, 1992;
Pietrzak et al., 2006, 2008), drug-methylxanthine (Woziwodzka
et al., 2011, 2013b; Buchelnikov and Evstigneev, 2014; Piosik
et al., 2002, 2003, 2005, 2010; Ulanowska et al., 2005, 2007;
Gołunski et al., 2015, 2016) and drug-fullerene (Skamrova et al.,
2014) combinations. Detailed treatment of the interceptor action
within the framework of the ‘oligomer’ IPA theory was accom-
plished in refs. (Skamrova et al., 2014; Buchelnikov and Evstigneev,
2014). If the aggregation is ignored, KYN is taken zero and the quasi-
physiological conditions (4.3) are applied (N0zx0, y0[x0), equa-
tion (5.1) result in
ADzKhy0: (5.3)
This is the very important result which will be re-visited in
section 6.6. Application of the IPA theory to biological data
6.1. The point test on proliferating cell lines
The ‘point test’, i.e. comparison of AD factors for different drug-
interceptor systems at single concentration of interceptor, corre-
sponding to reproducible measurement of biological effect, was
M.P. Evstigneev et al. / Progress in Biophysics and Molecular Biology 149 (2019) 131e146 141reported in refs. (Evstigneev, 2010; Evstigneev et al., 2008). The
authors of refs (Evstigneev, 2010; Evstigneev et al., 2008). used the
data of measurements of apoptosis (Traganos et al., 1991a) induced
in human leukemia cell line by addition of three antibiotics
(mitoxantrone d NOV, doxorubicin d DOX, ellipticine d ELP)
alone and together with caffeine (CAF). The effect of addition of CAF
to the cell culture together with antibiotic had resulted in lowering
of the drugs' cytotoxicity, estimated in AD units as A
exp
D ðNOVÞ ¼
67%>AexpD ðDOXÞ ¼ 53%>AexpD ðELPÞ ¼ 27:5%. The computation of
AD within the framework of the ‘oligomer’ IPA theory well matched
the experimental sequence for NOV > DOX, which marked the first
instance of successful application of the IPA theory to biological
data. However, it failed for ELP, and the theoretically predicted
sequence had been independent of variation of the binding pa-
rameters used in computations. In contrast to NOV/DOX, ELP
demonstrates the synergywith CAF only at sequential addition, and
shows little interaction with it on simultaneous administration
(Traganos et al., 1991a). This falls out of the range of applicability of
the IPA theory (see section 4.1) and suggested that the ELP þ CAF
interaction is governed by mechanisms other than the interceptor/
protector.
6.2. Evaluation of biological data from concentration dependence of
induced biological effect in vitro
In order to ascertain whether the quantity AD may be used to
predict the change in the biological effect of drug on addition of
interceptor in vitro, the corresponding experimental apoptosis-
concentration curve, Aðy0Þ, measured in human leukemia cell line
HL-60 for the action of antibiotic topotecan in combination with
caffeine (Traganos et al., 1993), was evaluated in ref. (Evstigneev
et al., 2011a). Recalculation of the Aðy0Þ dataset into AD units
within the framework of the ‘oligomer’ theory had resulted in
satisfactory description of the experimental dataset. This result was
considered as a significant success of the IPA theory and indirectly
confirmed the appropriateness of the quasi-physiological condi-
tions (4.3) and the transferability of the binding parameters
measured in independent physico-chemical experiment to bio-
logical system in vitro. It was also shown that the accuracy of
determination of binding parameters (especially the hetero-
association constant) is an important factor for quantitation of
biological effect in drug-interceptor-DNA systems.
The set of successful applications of the IPA theory to different
drugs' combinations, described above, had increased a confidence
that it was not due to a lucky set of numbers used as input, but
reflects the general pattern of aromatic ligands targeting DNA. In ref
(Skamrova et al., 2014) it was assumed that if the biological synergy
in drug-interceptor pairs is governed mainly by physico-chemical
processes of molecular complexation, hence the observed effects
should not depend on the type of cellular system used. The studies
of the combined effects of aromatic drugs had been reported only
for proliferating cell systems, but the general features of its mani-
festations should be similar in proliferating and non-proliferating
cell cultures. Human buccal epithelium cells were selected as a
test system to verify this hypothesis, and fullerene C60 was taken as
an interceptor molecule (Skamrova et al., 2014). A concentration-
dependent restoration of the non-disturbed biological state of the
living cell exposed to various aromatic compounds was observed
on addition of pristine C60 fullerenes by means of assessment of
heterochromatin structure in the cell nucleus, barrier function of
cell membrane and the method of cell microelectrophoresis in
buccal epithelium cells. The experimental dependence of the
number of heterochromatin granules on the concentration of C60
fullerene in the drug-C60 systems tested has been sufficiently well
described within the framework of the ‘oligomer’ IPA theoryconsidering the sole action of the interceptor mechanism. An in-
dependent verification of the results was carried out against the
drug-caffeine systems, as the classical drug-interceptor systems
most well described in literature within the framework of the
interceptor/protector action. As a general result, additional strong
confirmation of the validity of the IPA theory was obtained. Later on
it was shown that C60 fullerene combined with DOX exerts inter-
ceptor action on proliferating cell lines in vitro and even in vivo
(Panchuk et al., 2015; Prylutska et al., 2014, 2015). In fact, this result
had been predicted a priori based on previous knowledge of the
pattern of drug-interceptor-DNA systems, which highlights the
predictive potential of the IPA theory.6.3. Evaluation of biological data from mutagenic test in mutagen-
interceptor system
Chlorophyllin (CHL) has long been recognized as a molecule
exerting pronounced antimutagenic potency against various aro-
matic DNA acting mutagens (Woziwodzka et al., 2013a; Dashwood
and Guo, 1992, 1993; Pietrzak et al., 2008). This effect has been
interpreted in terms of formation of non-covalent hetero-com-
plexes between the mutagen and CHL resulting in lower accessi-
bility of the mutagen to DNA (Woziwodzka et al., 2013a; Dashwood
and Guo, 1992, 1993; Pietrzak et al., 2008) (which is the interceptor
mechanism falling within the competency of the IPA theory).
The most representative example of the mutagen-chlorophyllin
systems matching the interceptor hypothesis is the antimutagenic
action of CHL against imidazo-quinoline type amines (IQ, 2-amino-
3-methylimidazo[4,5-f]quinoline) in Salmonella typhimurium strain
TA98 reviewed by Dashwood (Dashwood and Guo,1993). Statistical
treatment of large IQ-CHL dataset had led to a conclusion about a
linear correlation between the antimutagenic potency of chlor-
ophyllin, IC50 (which is the chlorophyllin concentration needed for
50% suppression of mutagenicity in the cell culture treated with IQ
mutagens), and the hetero-association constant of the formation of
IQ-CHL complexes, Kh:
IC50fKh: (6.1)
Eq. (6.1) currently remains the most classical and undisputed
demonstration of the validity of molecular complexation hypoth-
esis when explaining biological synergy in drug-interceptor-DNA
systems.
In ref (Buchelnikov and Evstigneev, 2014). it was shown that the
IC50 factor may be derived as a partial case of the IPA theory under
condition of the sole action of the interceptor mechanism (see
section 5.4). If the IC50 factor is given as the concentration of
chlorophyllin needed for 50% suppression of mutagenicity in the
mutagen test, hence the following substitutions are valid, viz.
y0≡IC50 and AD≡1=2. Further transformation of eq. (5.3) results in






where B is certain constant.
It is seen that there is a significant difference between eqs. (6.1)
and (6.2). Fitting of the Dashwood data (the left plot in Fig. 4 re-
drawn from ref (Dashwood and Guo, 1993).) with eq. (6.2) gives
much better goodness of fit as comparedwith the linear correlation
[see eq. (6.1)] initially reported in the cited paper (Fig. 4). It means
that the hyperbolic dependence of biological effect (expressed in
the form of the IC50 factor) and the physico-chemical parameter of
interaction (expressed in the form of Kh) reflects the fundamental
Fig. 4. Left plot: fitting of Dashwood (Dashwood and Guo, 1993) experimental data (re-drawn from ref (Buchelnikov and Evstigneev, 2014)). Right plot: The AD factor in drug-
fullerene systems as a function of C60 fullerene concentration (re-drawn from ref (Skamrova et al., 2014)).
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other possible mechanisms (such as the protector, or any other)
contribute negligibly to experimental observable.
The success in description of the link between the biological and
physico-chemical data in mutagen-chlorophyllin systems within
the framework of the IPA theory enabled to suggest that similar
correlation should be observed for other interceptors as well. With
the use of mutagen test in Vibrio harveyi A16 strain the authors of
ref (Woziwodzka et al., 2011). reported the dependence of muta-
genic activity of the IQ-type amines on the concentration of various
xanthines, y0, among which the caffeine (CAF) had exerted the
most pronounced effect. In ref (Buchelnikov and Evstigneev, 2014).
these biological datawere recalculated into AD units, and the ADðy0Þ
dependence was computed under the sole action of the interceptor
mechanism. A good fitting of experimental data was reported
suggesting that the IQ-CAF systems follow the interceptor mecha-
nism in the sameway as the IQ-CHL systems discussed above, and is
well described by the IPA theory.7. The problem of interrelation of the interceptor/protector
actions
The separate protector and interceptor mechanisms are well
characterized in biophysical chemistry and can be quantified by
various experimental techniques, whereas there is problem of
quantitation for their simultaneous operation in drug-interceptor-
DNA systems. Traditional view is grounded on experimentally
detectable binding of interceptor to drug and interceptor to DNA as
a criterion to judge on whether this or that mechanism may be
ignored. Currently there is a general agreement between different
research groups concerning the role of the interceptor mechanism
(Buchelnikov et al., 2012; Gołunski et al., 2013), however, the
problem holds with respect to the importance of the protector
mechanism. The methylxanthines and chlorophyllin were tradi-
tionally treated by UVeVis spectroscopy which detected negligible
binding with DNA and allowed to rule out the protector mechanism
in majority of publications (e.g. refs (Hill et al., 2011; Woziwodzka
et al., 2011; Woziwodzka et al., 2013b; Kapuscinski et al., 2002;
Traganos et al., 1991a; Lyles and Cameron, 2002; Bedner et al.,
2001; Dashwood and Guo, 1993; Pietrzak et al., 2008; Pietrzak
et al., 2006)). As a consequence, it goes in severe contradiction
with the conclusions of the IPA theory, which predicts comparable
contribution from the interceptor and protector actions (see section
4.4). The ignoring of the protector mechanism creates difficulties in
interpreting the following facts:(i) Direct measurement of the interceptor-DNA binding constant
is commonly non-trivial by UVeVis due to spectral overlap and the
relative insensitivity of this technique to small binding constants
measured in low concentration range. In contrast the NMR mea-
surements (Hernandez Santiago et al., 2009; Davies et al., 2001),
DNA unwinding experiments (Tornaletti et al., 1989) and molecular
modeling studies (Deriabina et al., 2006) evidence the CAF-DNA
binding. Indirect UVeVis study of the three-component drug-
CAF-DNA system (Baranovsky et al., 2009) and direct NMR study of
CAF-DNA system (Davies et al., 2001) reported nearly similar
complexation constant KYNz 200M
1. This constant is close to
average drug-CAF hetero-association constants, Kh (e.g. refs
(Evstigneev, 2010; Evstigneev et al., 2008; Piosik et al., 2010;
Gołunski et al., 2015; Evstigneev, 2014)), suggesting that the
strengths of protector and interceptor bindings could be
commensurable. Moreover, the binding of methylxanthines to
native DNA is getting more tight (KYN increases 10-fold) in the
presence of divalent metal ions (Maria Johnson et al., 2012);
(ii) The CAF-DNA complexation constant, KYN , is ca. 1000 times
lower than the typical drug-DNA complexation constants, KXN (e.g.
refs (Evstigneev, 2010; Evstigneev et al., 2008; Piosik et al., 2010;
Gołunski et al., 2015)), however, the concentration, y0, of caffeine in
typical drug-interceptor-DNA systems which causes synergistic
effect, falls in mM range (e.g. refs (Traganos et al., 1993; Skamrova
et al., 2014; Traganos et al., 1991a; Traganos et al., 1991b)). The
latter is ca. 1000 times higher than that of the drug, x0. It follows
that the concentration of the interceptor-DNA complexes may
commensurate with the concentration of drug-DNA complexes
(which induce biological effect) and the ignoring of protector
mechanism may thus be incorrect;
(iii) with an aim to assess the importance of the protector
mechanism two independent groups used UVeVis spectroscopy
and generally similar mass balance equations (described in section
5.1), but obtained contradictory conclusions (Buchelnikov et al.,
2012; Gołunski et al., 2013);
(iv) the attempt to approach understanding the microscopic
picture of simultaneous drug-interceptor binding with DNA
was reported in ref. (Maria Johnson et al., 2003a). By means
of time correlated single photon counting it was demon-
strated that the interceptor binding is not limited to
complexationwith free drug molecules, but also includes the
binding with drug sitting in DNA, which indirectly indicates
the importance of the protector mechanism;
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originates from the difficulty of experimental decomposition of
their effects, which remains a challenge for further studies.
8. The major function of the IPA theory
Generalizing the above-formulated elements of the IPA theory,
its function as a biophysical method of investigation may be sum-
marized as follows:
(i) interpretation of the in vitro biological synergy on simulta-
neous administration of DNA targeting aromatic drugs and
interceptor molecules from single viewpoint, which is the
action of two molecular complexation processes in three-
component drug-interceptor-DNA system, viz. the protector
and interceptor actions;
(ii) explanation/prediction of experimental correlation between
the binding parameters and biological effect in drug-
interceptor-DNA systems;
(iii) quantitative estimation of the strengths of interceptor and
protector actions (the RD factor);
(iv) quantitative estimation of the relative change of biological
effect of drug on addition of interceptor (the AD factor). The
possibility to categorize different drugs on their sensitivity to
addition of the given interceptor, or different interceptors by
their ability to influence biological activity of the given drug;
(v) possibility to predict biological synergy for certain combi-
nations of aromatic drugs based on their ability to form
complexes in solution;
(vi) in practical aspect the IPA theory, apart from extension of
current scientific knowledge, may also be important in the
context of rational drug design for managing drug's response
by changing the physico-chemical parameters of molecular
complexation.9. Conclusion
The theory of interceptor-protector action (the IPA theory) is
probably the only currently known example of self-consistent
biophysical theory establishing a quantitative interrelation be-
tween parameters measured in independent physico-chemical
experiment and in vitro biological experiment for the class of
DNA binding drugs. The elements of the theory (basic assumptions,
mass balance equations, link to biological experiment etc) provide
complete algorithm of analysis, viz. formulation of the mechanism
of the observed effects, construction of quantitative model, plan-
ning of numerical experiment, theory-to-experiment assessment,
which may potentially be applied to any system of DNA targeting
aromatic drugs. Such analytical schemes, apart from extension of
current scientific knowledge, are important in the context of
rational drug design for managing drug's response by changing the
physico-chemical parameters of molecular complexation.
10. Perspectives for further development of the IPA theory
10.1. Analysis in case of different specificities of drug and
interceptor binding with DNA
As noted above the system of mass balance equations, being the
central element of the IPA theory, can be simply re-written for the
case of taking into account the specificity of ligand-DNA binding
(e.g. cooperativity, non-equivalent binding sites etc.). Under such
conditions the interrelation of interceptor/protector actions will
change.10.2. Application to other than DNA drug-interceptor-bioreceptor
systems
One of themost attractive directions would be the application of
the IPA theory to drug-interceptor-enzyme systems. As discussed
above, the current level of theory developed with respect to com-
bined action of drugs on proteins is the competitive binding of N-
type ligands with protein (Wang et al., 1998), i.e. the interceptor
mechanism is ignored. In terms of drug-biopolymer binding the
DNA and protein molecules are typically represented as one-
dimensional lattice. Hence, the mass balance equations construc-
tion will be identical for DNA and protein (if the structural factors
are not taken into account). Alternatively, the mass balance equa-
tions may be replaced with the equations of ligand-protein binding
which are well-reviewed in literature and account for various
specificities of binding. The main problem to be faced in such
analysis should be the parameterization of mass balance equations,
viz. the determination of the concentration of binding sites, N0,
available for drugs’ complexation in vitro.
Another attractive issue will be the investigation of drug-
interceptor-RNA systems. The variability of RNA structure will
likely require strict account for interceptor/protector actions even
for typical interceptor molecules. For example, the binding of
methylxanthines with RNAmay be relatively strong (Maria Johnson
et al., 2003b).
10.3. Application to new interceptor molecules
So far the interceptor/protector binding studies were performed
with respect to naturally existing interceptor molecules, such as
methylxanthines and polyphenols (see section 2). However, the
synthetic molecules, such as fullerenes and carbon nanotubes,
seem to also have a potential to be used as interceptor drugs and
thereby fall within the competency of the IPA theory.
As already discussed above the biological synergy of aromatic
DNA binding drugs administered together with C60 fullerene was
recently reported in vitro (Skamrova et al., 2014; Panchuk et al.,
2015; Prylutska et al., 2017b; Borowik et al., 2018) and in vivo
(Panchuk et al., 2015; Prylutska et al., 2014, 2015). C60 fullerene
effectively complex DNA binding drugs (Borowik et al., 2018;
Bilobrov et al., 2019; Evstigneev et al., 2013; Prylutskyy et al., 2014,
2015a, 2015b) and the in vitro action of fullerene for several studied
drugs is well described by the IPA theory (Skamrova et al., 2014).
Similar situation seems to be the case for carbon nanotubes (CNT),
which bind small molecules (Albertorio et al., 2009; Karachevtsev
and Karachevtsev, 2011; Buchelnikov et al., 2014a, 2014b). It has
been reported that the non-covalent complexation of aromatic
antitumor antibiotics with CNTs may act as a regulator of their
biological action (Ali-Boucetta et al., 2008; Liu et al., 2009) in the
same way as for DNA binding aromatic drugs. In particular, the
adsorption of drug on CNT surface results in lowering of its active
concentration in solution thereby limiting its binding with bio-
receptor (Ali-Boucetta et al., 2008; Liu et al., 2009).
10.4. Experimental decomposition of the strengths of the
interceptor/protector actions
As discussed above this issue remains the most difficult and
contradictory point of the IPA theory, and remains as a challenge for
further studies.
10.5. Application to protein-DNA systems
Important case for application of the IPA theory could be the
competitive binding of transcription factors to DNA resulting in
M.P. Evstigneev et al. / Progress in Biophysics and Molecular Biology 149 (2019) 131e146144gene regulation and commonly described by similar statistical-
thermodynamical approach to that used above for quantifying
drug binding with DNA (e.g. refs (Bintu et al., 2005; Teif, 2007; Segal
et al., 2008; Teif and Rippe, 2010)). There is much similarity be-
tween the way how the link between physico-chemical parameters
of complexation and biological data is established in the IPA theory
and the protein-DNA binding models. The latter uses the assump-
tion that the level of gene expression is proportional to the equi-
librium probability that protein is bound to the gene of interest
(Bintu et al., 2005; Segal et al., 2008), whereas the IPA theory as-
sumes that the change in biological effect of the drug is propor-
tional to the change in its concentration boundwith DNA (i.e. the AD
factor, see section 4.2). However, unlike the existing protein-DNA
binding theories, the IPA theory additionally takes into account
the ligand-ligand hetero-association. If that is important in gene
regulation, the IPA theory might provide a template for further
development of the protein-DNA binding models.
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